FDA to Finalize Mobile Medical App Rules Following Bill Passage

Fenwick & West Life Sciences Group
Contact

[author: Michael Shuster]

Yesterday, the Senate approved the Food and Drug Administration Safety and Innovation Act (FDASIA) which provides reauthorization for major components of the Prescription Drug User Fee Act (PDUFA) set to expire at the end of September. An important development not being widely covered, is that the reconciled bill removes language that had been added by the Senate prohibiting the Food and Drug Administration (FDA) from final rulemaking on mobile medical apps and related technologies. As a result, the FDA is now free to issue final rules providing guidance for this rapidly growing industry. FDA draft guidance on mobile medical apps was issued in July of 2011. The legislative move is seen as a positive development for the emerging digital health sector.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Fenwick & West Life Sciences Group

Written by:

Fenwick & West Life Sciences Group
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Fenwick & West Life Sciences Group on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide